Baird analyst David Rescott raised the firm’s price target on Medtronic (MDT) to $109 from $103 and keeps a Neutral rating on the shares. The firm updated its model as its investment in growth adds to the story but OM expansion continues to lag.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic price target raised to $114 from $100 at Wells Fargo
- Cautious Hold Rating on Medtronic Amid Mixed Segment Performance and Uncertain Growth Prospects
- Medtronic price target raised to $111 from $98 at Bernstein
- Medtronic’s Strategic Growth and Cautious Optimism Amid Fiscal Gains and Investment Needs
- Medtronic Reports Strong Q2 2026 Financial Results